Takada Yukihisa, Sumioka Takayoshi, Nakagawa Masaki, Saika Shizuya
Department of Ophthalmology, Wakayama Medical University, Wakayama, Japan.
Department of Ophthalmology, Saiseikai Arida Hospital, Wakayama, Japan.
Taiwan J Ophthalmol. 2020 Mar 5;10(2):95-99. doi: 10.4103/tjo.tjo_77_19. eCollection 2020 Apr-Jun.
We examined intraocular pressure (IOP)-reducing effects 12 months after switching timolol maleate/travoprost combination ophthalmic solution in one bottle (TM/TR-COMBI-SOL) to carteolol hydrochloride/latanoprost combination ophthalmic solution in one bottle (CR/LT-COMBI-SOL).
The participants included 25 patients (25 eyes) who could be followed up for 12 months after a switch from TM/TR-COMBI-SOL to CR/LT-COMBI-SOL in Saiseikai Arida Hospital between March 1, 2017, and August 31, 2018. They consisted of patients in whom antiglaucoma eye drop other than TM/TR-COMBI-SOL had not been used (monotherapy group, 12 patients [12 eyes], 12.8 ± 3.0 mmHg) and those in whom antiglaucoma eye drop other than TM/TR-COMBI-SOL had been concomitantly used (multitherapy group, 13 patients [13 eyes], 13.8 ± 2.4 mmHg). We excluded patients in whom drugs for glaucoma were changed or added during the follow-up and those who underwent intraocular surgery.
We retrospectively and statistically examined the IOP before eye drop switching and after 1, 6, and 12 months, using the paired -test.
The IOPs 1 month after eye drop switching in the monotherapy group and multitherapy group were 12.5 ± 3.3 and 13.8 ± 2.5 mmHg, respectively. The values after 6 months were 13.5 ± 3.0 and 11.5 ± 2.7 mmHg, respectively. Those after 12 months were 12.8 ± 2.7 and 11.7 ± 2.5 mmHg, respectively. In the monotherapy group, there was no significant difference during the follow-up period. In the multitherapy group, there were significant decreases in comparison with the preswitching value after 6 and 12 months ( < 0.05, respectively).
The IOP-reducing effects of CR/LT-COMBI-SOL were similar to those of TM/TR-COMBI-SOL. However, the effects may be enhanced after switching from TM/TR-COMBI-SOL in patients receiving multitherapy.
我们研究了在将一瓶中的马来酸噻吗洛尔/曲伏前列素复方滴眼液（TM/TR-COMBI-SOL）换成一瓶中的盐酸卡替洛尔/拉坦前列素复方滴眼液（CR/LT-COMBI-SOL）12个月后降低眼压（IOP）的效果。
研究对象包括2017年3月1日至2018年8月31日期间在西日本爱媛县立医院从TM/TR-COMBI-SOL换成CR/LT-COMBI-SOL后可随访12个月的25例患者（25只眼）。其中包括未使用过TM/TR-COMBI-SOL以外的抗青光眼滴眼液的患者（单药治疗组，12例患者[12只眼]，眼压为12.8±3.0 mmHg）以及同时使用过TM/TR-COMBI-SOL以外的抗青光眼滴眼液的患者（联合治疗组，13例患者[13只眼]，眼压为13.8±2.4 mmHg）。我们排除了随访期间更换或添加青光眼药物的患者以及接受过眼内手术的患者。
我们采用配对t检验，回顾性地并通过统计学方法检查了更换滴眼液前以及更换后1、6和12个月时的眼压。
单药治疗组和联合治疗组在更换滴眼液1个月后的眼压分别为12.5±3.3 mmHg和13.8±2.5 mmHg。6个月后的眼压值分别为13.5±3.0 mmHg和11.5±2.7 mmHg。12个月后的眼压值分别为12.8±2.7 mmHg和11.7±2.5 mmHg。在单药治疗组中，随访期间无显著差异。在联合治疗组中，与更换前的值相比，6个月和12个月后眼压有显著降低（P均<0.05）。
CR/LT-COMBI-SOL降低眼压的效果与TM/TR-COMBI-SOL相似。然而，在接受联合治疗的患者中，从TM/TR-COMBI-SOL更换后效果可能会增强。
